Posts Tagged: "Trade Related Aspects of Intellectual Property Rights"

Renegotiate NAFTA to Make it the Gold Standard in IP Protection

As President Trump embarks on the renegotiation of NAFTA, it is critical that we seize the opportunity to make it the gold standard in intellectual property rights protections… The stakes are tremendous and cannot be ignored.  In total, it is estimated that intellectual-property theft costs the United States approximately $600 billion per year.  A recent New York Times article notes that this is the “greatest transfer of wealth in history”.

What happens when lifestyle drugs like Viagra and Cialis lose patent protections?

Each year, millions of men rely on pharmaceuticals like Viagra and Cialis for their erectile dysfunction (ED), but they may not be the only ones facing dysfunctionalities. As the patents on these lucrative lifestyle drugs come to an end, price tags and bottom lines are expected to plummet… The lifestyle drug market is extremely lucrative. These medications can be used by all age groups worldwide and increased individual awareness of health and beauty has created a demand for physical fitness and improved performance of all our body parts. People are living longer, have higher disposable income, and the demand only grows more when a drug touts the high quality and safety of their formulations after it passes the stringent requirements for FDA approval… The real question, however, is whether U.S. patent law and policy will continue to give pharmaceutical companies the incentives necessary to innovate lifesaving medicines, or whether we will continue to see more and more blockbuster lifestyle drugs moving into the future.

UN Secretary General’s Panel on Access to Medicines Reports: Government Knows Best

Delayed for months beyond its expected issue date the Secretary General’s High Level Panel on Access to Medicine’s report emerged yesterday. Apparently the panelists scrambled to better disguise their predetermined agenda behind reams of soothing rhetoric. While lip service is given to the unimagined advances in medicine under the current industry led drug development system, that’s quickly discarded under the pretext of providing better access to health care for the world’s poorest citizens through a system run by international bureaucracy. These recommendations are largely directed at the US life science industry. Luckily, one panel member provides an effective rebuttal to this approach but unless his message is repeated many public officials, media outlets and the general public could come to accept that a government run system would be “more fair.”